China Powers Into Precision Medicine
This article was originally published in PharmAsia News
Metastatic tumors, diabetes, cardiovascular and rare diseases are among the areas being targeted in China’s new precision medicine initiative, in a bet that could be worth $10 billion by 2030.
You may also be interested in...
2016 is the year for precision medicine therapies to be included in China’s National Major Project for Innovation. Looking to seize market opportunity in the newly funded area, Huapont Life Sciences has linked up with and invested in a US bioventure partner for a gene therapy for refractory angina.
China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.
2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.